Document is current
Any future updates will be listed below
-
Authors
Thavaneswaran, Subotheni http://orcid.org/0000-0002-8946-6709
Kansara, Maya
Lin, Frank
Espinoza, David
Grady, John P. http://orcid.org/0000-0001-9667-3872
Lee, Chee Khoon
Ballinger, Mandy L.
Sebastian, Lucille
Corpuz, Theresa
Qiu, Min Ru
Mundra, Piyushkumar
Bailey, Charles G.
Schmitz, Ulf http://orcid.org/0000-0001-5806-4662
Simes, John
Joshua, Anthony M. http://orcid.org/0000-0001-5159-4580
Thomas, David M.
-
Funding
Funding for this research was provided by:
OHMR - Health Administration Corporation as represented by the Ministry of Health Commonwealth Government Grant (GO 1964) MRFF Emerging Priorities and Consumer Driven Research initiative
- License Information
-
More Information
Article History
Received: 20 October 2022
Revised: 8 May 2023
Accepted: 5 June 2023
First Online: 26 June 2023
Competing interests
: DT as CEO of Omico, a non-profit organisation has received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene, Elevation Oncology, RedX Pharmaceuticals, Sun-Pharma, Bayer, Abbvie, George Clinical, Janssen, Merck, Kinnate, Microba, BioTessellate, Australian Unity, Foundation Medicine, Guardant, Intervenn, Amgen, Seattle Genetics and Eli Lilly. DT also serves on the advisory boards or committees for Canteen, UNSW SPHERE and NSW government in respect to genomics and translational medicine.
: Not applicable.
: Not applicable.
